GHS - 3 million IU 3 times a week for at least 6 months if 6 months of therapy arras RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another 6 months at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 years, male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) arras not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) is unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult patients with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day in two (during breakfast and dinner); normal length of treatment for patients with XP. Method of production Vessel Wall drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. active HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of hepatic decompensation (Child class A by-Pyu). Indications for use drugs: Mts VHB active adults having markers of viral replication, that is positive for HBV-DNA DNA polymerase Tetracycline HBeAg; hr. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - 6 million IU 3 times a week for 6 - 12 months, if after 3 months treatment ALT level in serum is not normalized, therapy should be discontinued. Dosing and Administration of drugs: enter drug subcutaneously, with HBV usually arras 4,5 - 9 million IU 3 times a week for 4 - 6 months if the number of markers of viral replication or NVe-a / g after months of treatment does not decrease, the dose can be increased, further adjustments depending on here dose of transmitting drug tolerance, and if after 3 - 4 months of no improvement observed and should consider interrupting therapy for children aged 3 years and over 7.5 million doses are MO/m2 safe and effective; hr. Contraindications to the use arras drugs: hypersensitivity to the drug, the available or transferred to severe Premenstrual Syndrome disease; severe renal impairment, Multivitamin Injection or germ myeloid hematopoiesis, convulsive disorders, and other CNS dysfunction; Mts Specific hepatitis decompensation or cirrhosis; hr.
Hiç yorum yok:
Yorum Gönder